Literature DB >> 21472488

Does Kaposi's sarcoma predict multicentric Castleman disease in the presence of generalized lymphadenopathy?

Homam Alkaied1, Kassem Harris, Dany Elsayegh, Inga Khachaturova, Michael Awasum, Seema Varma.   

Abstract

Multisystemic Castleman disease (MCD) can be associated with HHV8 infection, which involves the mantle zone of follicles. This condition results in an increase number of HHV8-positive (HHV8+) plasmablasts that multiply and amalgamate to form plasmablastic B-cell lymphoma. All previously reported cases of HIV-positive patients with MCD were coinfected with HHV8. Twelve cases of HIV- MCD that are HHV8+ were encountered in the literature, three of them developed lymphoma, and none of those cases were reported to have Kaposi's sarcoma (KS). We report a unique case of HIV-negative elderly woman with preexisting KS that presented to the hospital with recurring nausea, vomiting, and fever, assessment revealed diffuse lymphadenopathy. Axillary lymph node biopsy showed HHV8+ MCD with foci of microlymphoma. Despite the treatment with high-dose steroids, she developed multisystem failure that lead to her death.

Entities:  

Mesh:

Year:  2011        PMID: 21472488     DOI: 10.1007/s12032-011-9886-z

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  22 in total

1.  Effects of bortezomib on pro-inflammatory cytokine levels and transfusion dependency in a patient with multicentric Castleman disease.

Authors:  Georg Hess; Volker Wagner; Andreas Kreft; Claus Peter Heussel; Christoph Huber
Journal:  Br J Haematol       Date:  2006-09       Impact factor: 6.998

2.  Near-total resolution of multicentric Castleman disease by prolonged treatment with thalidomide.

Authors:  Cindi R Starkey; Nancy E Joste; Fa-Chyi Lee
Journal:  Am J Hematol       Date:  2006-04       Impact factor: 10.047

3.  Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases.

Authors:  D D Weisenburger; B N Nathwani; C D Winberg; H Rappaport
Journal:  Hum Pathol       Date:  1985-02       Impact factor: 3.466

4.  A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients.

Authors:  G Frizzera; B A Peterson; E D Bayrd; A Goldman
Journal:  J Clin Oncol       Date:  1985-09       Impact factor: 44.544

5.  HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma.

Authors:  N Dupin; T L Diss; P Kellam; M Tulliez; M Q Du; D Sicard; R A Weiss; P G Isaacson; C Boshoff
Journal:  Blood       Date:  2000-02-15       Impact factor: 22.113

6.  Detection of human herpesvirus-8 in peripheral blood mononuclear cells from adult Japanese patients with multicentric Castleman's disease.

Authors:  Satoshi Yamasaki; Tadafumi Iino; Minoru Nakamura; Hideho Henzan; Koichi Ohshima; Masahiro Kikuchi; Teruhisa Otsuka; Mine Harada
Journal:  Br J Haematol       Date:  2003-02       Impact factor: 6.998

Review 7.  Castleman's disease and lymphoma: report of eight cases in HIV-negative patients and literature review.

Authors:  Claire Larroche; Patrice Cacoub; Jean Soulier; Eric Oksenhendler; Jean-Pierre Clauvel; Jean-Charles Piette; Martine Raphael
Journal:  Am J Hematol       Date:  2002-02       Impact factor: 10.047

8.  The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease.

Authors:  T Powles; J Stebbing; A Bazeos; E Hatzimichael; S Mandalia; M Nelson; B Gazzard; M Bower
Journal:  Ann Oncol       Date:  2009-01-29       Impact factor: 32.976

9.  Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial.

Authors:  Laurence Gérard; Alice Bérezné; Lionel Galicier; Véronique Meignin; Martine Obadia; Nathalie De Castro; Christine Jacomet; Renaud Verdon; Isabelle Madelaine-Chambrin; Emmanuelle Boulanger; Sylvie Chevret; Felix Agbalika; Eric Oksenhendler
Journal:  J Clin Oncol       Date:  2007-08-01       Impact factor: 44.544

10.  Brief communication: rituximab in HIV-associated multicentric Castleman disease.

Authors:  Mark Bower; Tom Powles; Sarah Williams; Tom Newsom Davis; Mark Atkins; Silvia Montoto; Chloe Orkin; Andy Webb; Martin Fisher; Mark Nelson; Brian Gazzard; Justin Stebbing; Peter Kelleher
Journal:  Ann Intern Med       Date:  2007-12-18       Impact factor: 25.391

View more
  2 in total

Review 1.  Clinical features and outcome of patients with HIV-negative multicentric Castleman's disease treated with combination chemotherapy: a report on 10 patients.

Authors:  Shou-Hui Zhu; Yong-Hua Yu; Yong Zhang; Ju-Jie Sun; Da-Li Han; Jia Li
Journal:  Med Oncol       Date:  2013-02-12       Impact factor: 3.064

2.  Multicentric Castleman's Disease and Kaposi's Sarcoma in a HIV-Positive Patient on Highly Active Antiretroviral Therapy.

Authors:  Lauro Ortega; Chad J Cooper; Salman Otoukesh; Mona Mojtahedzadeh; Claudia S Didia; Alireza Torabi; Zeina Nahleh
Journal:  Rare Tumors       Date:  2014-08-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.